Lancashire and South Cumbria
Formulary
Formulary
3 Respiratory system
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
03-04-03 Angioedema
| Berotralstat dihydrochloride Orladeyo® |
|
Formulary
|
Capsules 150mg |
 NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema |
|
500iu powder and solvent for solution for injection| Garadacimab Andembry® |
|
Formulary
|
Solution for injection in pre-filled pen
Routine commissioning will be via specialised commissioned centres which, for the North West (NW) region are:
Alder Hey Children’s Hospital NHS Foundation Trust
Lancashire Teaching Hospitals NHS Foundation Trust
Liverpool University Hospitals NHS Foundation Trust
Manchester University NHS Foundation Trust
Northern Care Alliance NHS Foundation Trust
|
|
NICE TA1101: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over |
|
|
| Icatibant |
|
Formulary
|
30mg solution for injection in pre-filled syringe |
|
NHSE: Icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor |
|
|
| Lanadelumab Takhzyro® |
|
Formulary
|
300mg solution for injection in pre-filled syringe |
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
|
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Asthma action plan child: Asthma UK- Asthma management plan: Asthma UK
- Biosimilars policy statement
- BNF: Antihistamines, allergen immunotherapy and allergic emergencies
- LSCMMG: Asthma Treatment Guideline for Adults (aged 12 and over)
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: COPD Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Adrenaline auto-injectors (AAIs): new guidance and resources for safe use
- MHRA: Guidance for patients
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NHSE: Icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG134: Anaphylaxis: assessment and referral after emergency treatment
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA1101: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
- NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema